Article
Long-term, low-dose warfarin among venous thrombosis patients with and without factor V Leiden mutation: rationale and design for the Prevention of Recurrent Venous Thromboembolism (PREVENT) trial.
Vascular medicine (London, England) - 1 Jan 1998
Ridker P M
Abstract excerpt
Standard therapy for patients with deep venous thrombosis and pulmonary embolism typically includes anticoagulation for a 3-6 month period with full dose warfarin. However, patients following this regimen experience high rates of recurrent thrombosis, re-hospitalization and mortality in the years...
Topics
- Adult
- Aged
- Aged, 80 and over
- Anticoagulants
- Factor V
- Female
- Humans
- Male
- Middle Aged
- Mutation
- Pulmonary Embolism
- Research Design
- Secondary Prevention
- Thrombophlebitis
- Warfarin